347 Results

People

  1. Mauro
    Mauro
  2. Clarkson
    Clarkson
  3. Berman
    Berman
  4. O'Reilly
    O'Reilly
  5. Strife
    Strife
  6. Wisniewski
    Wisniewski
  7. Kernan
    Kernan
  8. Sawyers
    Sawyers
  9. Scheinberg
    Scheinberg
  10. Papadopoulos
    Papadopoulos

Groups

  1. Department of Medicine (242)
  2. Hematologic Malignancies, Division of (207)
  3. Center for Hematologic Malignancies (182)
  4. Adult Leukemia (117)
  5. Sloan Kettering Institute Faculty (108)
  6. GSK Faculty (106)
  7. Tow Center for Developmental Oncology (TCDO) (77)
  8. Molecular Pharmacology and Chemistry Program Faculty (71)
  9. Human Oncology and Pathogenesis Program (47)
  10. Pediatrics, Department of (46)
  1. "chronic myeloid leukemia"
Formats
  1. Journal Article (300)
  2. Meeting Abstract (18)
  3. Review (10)
  4. Conference Paper (8)
  5. Research Letter (6)
  6. Correspondence (2)
  7. Editorial (2)
  8. Guidelines (1)
Groups
  1. Department of Medicine (242)
  2. Hematologic Malignancies, Division of (207)
  3. Center for Hematologic Malignancies (182)
  4. Adult Leukemia (117)
  5. Sloan Kettering Institute Faculty (108)
  6. GSK Faculty (106)

More Groups

People
  1. Michael Mauro (56)
  2. Bayard Clarkson (40)
  3. Ellin Berman (24)
  4. Annabel Strife (20)
  5. Richard O'Reilly (20)
  6. David Wisniewski (18)

More People

Years
  1. 2025 (7)
  2. 2024 (16)
  3. 2023 (20)
  4. 2022 (13)
  5. 2021 (4)
  6. 2020 (8)

More Years

Publications
  1. Blood (29)
  2. Leukemia (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (19)
  4. Biology of Blood and Marrow Transplantation (17)
  5. Bone Marrow Transplantation (15)
  6. Cancer Research (14)

More Publications

Publishers
  1. Elsevier Inc. (51)
  2. Nature Publishing Group (51)
  3. American Society of Hematology (33)
  4. American Association for Cancer Research (20)
  5. John Wiley & Sons (12)
  6. Springer (12)

More Publishers

Results (347)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: A landmark analysis
    Journal Article

    Berdeja, J. G.; Heinrich, M. C.; Dakhil, S. R.; Goldberg, S. L.; Wadleigh, M.; Kuriakose, P.; Cortes, J.; Radich, J.; Helton, B.; Rizzieri, D.; more...
    Leukemia and Lymphoma (2019)

    Fulltext@MSK | Save
  • Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms
    Review

    Mughal, T. I.; Pemmaraju, N.; Radich, J. P.; Deininger, M. W.; Kucine, N.; Kiladjian, J. J.; Bose, P.; Gotlib, J.; Valent, P.; Chen, C. C.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Targeted therapies for myeloproliferative neoplasms
    Review

    Li, B.; Rampal, R. K.; Xiao, Z.
    Biomarker Research (2019)

    Fulltext@MSK | Save
  • Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia
    Journal Article

    Cortes, J. E.; Gambacorti-Passerini, C.; Deininger, M. W.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Milojkovic, D.; le Coutre, P.; Garcia-Gutierrez, V.; Crescenzo, R.; more...
    Journal of Cancer Research and Clinical Oncology (2019)

    Fulltext@MSK | Save
  • DASFREE: An 18-month update of dasatinib discontinuation in patients with chronic myeloid leukemia in chronic phase and deep molecular response
    Meeting Abstract

    Shah, N. P.; García-Gutiérrez, V.; Jiménez-Velasco, A.; Larson, S.; Saussele, S.; Rea, D.; Mahon, F. X.; Levy, M. Y.; Gómez-Casare, M. T.; Pane, F.; more...
    British Journal of Haematology (2019)

    Fulltext@MSK | Save
  • Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: A randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
    Journal Article

    Bolaños-Meade, J.; Reshef, R.; Fraser, R.; Fei, M.; Abhyankar, S.; Al-Kadhimi, Z.; Alousi, A. M.; Antin, J. H.; Arai, S.; Bickett, K.; more...
    The Lancet Haematology (2019)

    Fulltext@MSK | Save
  • Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms
    Journal Article

    Mughal, T. I.; Lion, T.; Abdel-Wahab, O.; Mesa, R.; Scherber, R. M.; Perrotti, D.; Mauro, M.; Verstovsek, S.; Saglio, G.; Van Etten, R. A.; more...
    Hematological Oncology (2018)

    Fulltext@MSK | Save
  • Treatment-free remission (TFR) in patients with chronic-phase chronic myeloid leukemia (CML-CP) and stable deep molecular response (DMR) discontinuing dasatinib (DASFREE)
    Meeting Abstract

    Shah, N. P.; Garcia-Gutiérrez, J. V.; Jiménez-Velasco, A.; Larson, S.; Saussele, S.; Rea, D.; Mahon, F. X.; Levy, M. Y.; Gómez-Casares, M. T.; Pane, F.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2018)

    Fulltext@MSK | Save
  • Clinical development of asciminib (ABL001): A randomized phase 3 study of asciminib vs bosutinib in patients with chronic myeloid leukemia (CML)
    Meeting Abstract

    Mauro, M. J.; Lang, F.; Kim, D. W.; Cortes, J. E.; Hughes, T. P.; Hochhaus, A.; Minami, H.; Boquimpani, C.; Minami, Y.; Breccia, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2018)

    Fulltext@MSK | Save
  • An observational study of survival in patients with chronic-phase chronic myeloid leukemia (CML-CP) after 1, 3, and 5 years of tyrosine kinase inhibitor (TKI) therapy (SIMPLICITY)
    Meeting Abstract

    Michallet, M.; Cortes, J.; Gambacorti-Passerini, C.; Hehlmann, R.; Williams, L. A.; Goldberg, S. L.; Davis, C.; De Solda, F.; Sen, G. P.; Gajavelli, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2018)

    Fulltext@MSK | Save